Harvard Bioscience, Inc.

NasdaqGM:HBIO 株式レポート

時価総額:US$104.2m

Harvard Bioscience 将来の成長

Future 基準チェック /46

Harvard Bioscience利益と収益がそれぞれ年間98.1%と9.7%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に1.2% 98.8%なると予測されています。

主要情報

98.1%

収益成長率

98.8%

EPS成長率

Life Sciences 収益成長18.5%
収益成長率9.7%
将来の株主資本利益率1.2%
アナリストカバレッジ

Low

最終更新日08 Nov 2024

今後の成長に関する最新情報

Recent updates

Is Now An Opportune Moment To Examine Harvard Bioscience, Inc. (NASDAQ:HBIO)?

Nov 07
Is Now An Opportune Moment To Examine Harvard Bioscience, Inc. (NASDAQ:HBIO)?

Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt

Aug 07
Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares Not Telling The Full Story

Jul 15
Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares Not Telling The Full Story

Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely

Dec 22
Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price

Sep 23
Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price

Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Aug 10
Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued

Apr 26
An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt

Apr 11
Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt

Harvard Bioscience GAAP EPS of $0.05 beats by $0.06, revenue of $29.2M misses by $1.2M

Aug 04

Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt

Jun 08
Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt

Harvard Bioscience - Dressed Up And Waiting For A Suitor

Mar 15

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly

Feb 16
Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly

Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?

Nov 04
Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?

Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Trading At A 37% Discount?

Oct 01
Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Trading At A 37% Discount?

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 25% Undervalued

May 04
An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 25% Undervalued

These 4 Measures Indicate That Harvard Bioscience (NASDAQ:HBIO) Is Using Debt Extensively

Apr 19
These 4 Measures Indicate That Harvard Bioscience (NASDAQ:HBIO) Is Using Debt Extensively

Analysts Are Optimistic We'll See A Profit From Harvard Bioscience, Inc. (NASDAQ:HBIO)

Apr 04
Analysts Are Optimistic We'll See A Profit From Harvard Bioscience, Inc. (NASDAQ:HBIO)

Have Insiders Sold Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Recently?

Mar 20
Have Insiders Sold Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Recently?

What Kind Of Shareholders Hold The Majority In Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares?

Mar 07
What Kind Of Shareholders Hold The Majority In Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares?

Harvard Bioscience (NASDAQ:HBIO) Shareholders Have Enjoyed A 92% Share Price Gain

Feb 17
Harvard Bioscience (NASDAQ:HBIO) Shareholders Have Enjoyed A 92% Share Price Gain

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 35% Undervalued

Feb 02
An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 35% Undervalued

業績と収益の成長予測

NasdaqGM:HBIO - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/202612328121
12/31/2025103-2472
12/31/202496-12-212
9/30/202498-1404N/A
6/30/2024101-1169N/A
3/31/2024107-91114N/A
12/31/2023112-31214N/A
9/30/2023113-31112N/A
6/30/2023114-579N/A
3/31/2023115-245N/A
12/31/2022113-1001N/A
9/30/2022118-7-3-1N/A
6/30/2022121-4-4-3N/A
3/31/2022121-6-3-2N/A
12/31/2021119001N/A
9/30/2021117-224N/A
6/30/2021111-356N/A
3/31/2021105-467N/A
12/31/2020102-889N/A
9/30/2020102-789N/A
6/30/2020105-8911N/A
3/31/2020112-789N/A
12/31/2019116-578N/A
9/30/2019119-288N/A
6/30/2019120034N/A
3/31/2019122-144N/A
12/31/2018121-423N/A
9/30/2018109-8-2-1N/A
6/30/201899-8N/A3N/A
3/31/201886-7N/A2N/A
12/31/201777-2N/A1N/A
9/30/201782-3N/A4N/A
6/30/201788-4N/A5N/A
3/31/201796-4N/A5N/A
12/31/2016105-4N/A5N/A
9/30/2016106-20N/A5N/A
6/30/2016107-19N/A2N/A
3/31/2016110-18N/A0N/A
12/31/2015109-19N/A1N/A
9/30/2015111-2N/A0N/A
6/30/20151100N/A1N/A
3/31/20151090N/A3N/A
12/31/20141092N/A4N/A
9/30/20141062N/A4N/A
6/30/20141061N/A5N/A
3/31/20141051N/A5N/A
12/31/20131051N/A4N/A

アナリストによる今後の成長予測

収入対貯蓄率: HBIOは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 2.6% ) よりも高い成長率であると考えられます。

収益対市場: HBIO今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: HBIO今後 3 年以内に収益を上げることが予想されます。

収益対市場: HBIOの収益 ( 9.7% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: HBIOの収益 ( 9.7% ) 20%よりも低い成長が予測されています。


一株当たり利益成長率予想


将来の株主資本利益率

将来のROE: HBIOの 自己資本利益率 は、3年後には低くなると予測されています ( 1.2 %)。


成長企業の発掘